A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK

European Journal of Haematology

Volumn 78, Issue 6, 2007, Pages 532-539

  Bruynesteyn, Karin ^a   Gant, Vanya ^b   McKenzie, Catherine ^c   Pagliuca, Tony ^d   Poynton, Chris ^e   Kumar, Ritesh N ^f   Jansen, Jeroen P ^a  

^a MAPI GROUP   (Netherlands)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antifungal drugs; Cost effectiveness analysis; Cost utility analysis; Economic analysis; Empiric therapy; Fungal infections

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INFECTION; LIFE EXPECTANCY; MODEL; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SURVIVAL; UNITED KINGDOM;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; GREAT BRITAIN; HUMANS; LENGTH OF STAY; LIPOSOMES; MYCOSES; PEPTIDES, CYCLIC; QUALITY-ADJUSTED LIFE YEARS;

EID: 34248551085     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00850.x     Document Type: Article

References (17)

1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006 106 : 2258 66.
2. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993 167 : 1247 51.
3. Guiot HF, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994 18 : 525 32.
4. Bodey GP, Knotoyiannis DP, Lewis RE. Empiric antifungal therapy for persistently febrile neutropenic patients. Curr Treatm Opt Infect Dis 2002 4 : 521 32.
5. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 34 : 730 51.
6. Walsh TJ, Pappas P, Winston DJ, et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002 34 : 225 34.
7. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000 18 : 2476 83.
8. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 351 : 1391 402.
9. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999 340 : 764 71.
10. Jorgensen KJ, Gotzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006 1 : CD004707.
11. Ascioglu S, Rex JH, de Pauw B, et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34 : 7 14.
12. Boogaerts M, Winston DJ, Bow EJ, et al. Itraconazole Neutropenia Study Group. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001 135 : 412 22.
13. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000 108 : 282 9.
14. National Statistics, Survival data England 1998-2001. Office for National Statistics (ONS). http://www.statistics.gov.uk/statbase. Accessed September 2005.
15. Maertens J, Raad I, Petrikkos G, et al. Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 71.
16. NHS reference cost. Department of Health. http://www.dh.gov.uk/. Accessed September 2005.
17. De Pauw BE, Sable CA, Walsh TJ, et al. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transpl Infect Dis 2006 8 : 31 7.